Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up
Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular risk. Several traditional and disease-specific risk factors have been shown to correlate with the occurrence of cardiovascular events (CVE) in patients with SLE. However, results of previous studies are diverse. The ob...
Gespeichert in:
| Veröffentlicht in: | Seminars in arthritis and rheumatism 2023-08, Vol.61, p.152226-152226, Article 152226 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 152226 |
|---|---|
| container_issue | |
| container_start_page | 152226 |
| container_title | Seminars in arthritis and rheumatism |
| container_volume | 61 |
| creator | Farina, Nicola Webster, Jemma Luo, Weike Garelick, Daniela Pinto, Sara Moreira Isenberg, David Rahman, Anisur |
| description | Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular risk. Several traditional and disease-specific risk factors have been shown to correlate with the occurrence of cardiovascular events (CVE) in patients with SLE. However, results of previous studies are diverse. The objectives of this study were to report number, type and those factors associated with CVE in patients with SLE in a large, single-center, ethnically diverse cohort with a long follow-up duration.
Medical records of patients treated at the Lupus Clinic at University College London Hospital (UCLH) between 1979 and 2020 were retrospectively reviewed. Data about CVE, traditional cardiovascular risk factors, demographic and disease features, and treatment history were collected. Only patients with complete available information were included in the study. Regression analyses were performed to identify factors associated with CVE.
Four hundred and nineteen patients were included in the study. Maximum follow-up length was 40 years. Seventy-one (17%) patients had at least one CVE. Multivariable analysis showed that only antiphospholipid antibody positivity (p-value |
| doi_str_mv | 10.1016/j.semarthrit.2023.152226 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2816763746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049017223000689</els_id><sourcerecordid>2816763746</sourcerecordid><originalsourceid>FETCH-LOGICAL-c424t-6c5d4b4e9d32b3408a96516c9751695142f07fc6befdd2805e8b2909e526a4883</originalsourceid><addsrcrecordid>eNqFkcFu1DAQhi0EokvLKyAfuWSxHcdJjlBRQKrEpZW4WY490XqVxMFjb7UvwHPjNgWOXGYO8838M_MTQjnbc8bVh-MeYTYxHaJPe8FEveeNEEK9IDve1KLqlPrxkuwYk33FeCsuyBvEI2OcK9a-Jhd1KxgXXO7IrxtjU4hIDWKw3iRw9MGnA7UmOh9OBm2eTKRwgiUh9QvFMyaYvaVTXjNSiOd0KMukgPmpbugclmALHgtkwyHEtI3MK02BSkbPYIpiGOkYpik8VHm9Iq9GMyG8fc6X5P7m89311-r2-5dv1x9vKyuFTJWyjZODhN7VYqgl60yvGq5s35bYN1yKkbWjVQOMzomONdANomc9NEIZ2XX1JXm_zV1j-JkBk549Wpgms0DIqEXHVavqVqqCdhtqY0CMMOo1-vL0s-ZMP7qgj_qfC_rRBb25UFrfPavkYQb3t_HP2wvwaQOg3HryEDVaD4sF5yPYpF3w_1f5DQ90oFs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2816763746</pqid></control><display><type>article</type><title>Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Farina, Nicola ; Webster, Jemma ; Luo, Weike ; Garelick, Daniela ; Pinto, Sara Moreira ; Isenberg, David ; Rahman, Anisur</creator><creatorcontrib>Farina, Nicola ; Webster, Jemma ; Luo, Weike ; Garelick, Daniela ; Pinto, Sara Moreira ; Isenberg, David ; Rahman, Anisur</creatorcontrib><description>Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular risk. Several traditional and disease-specific risk factors have been shown to correlate with the occurrence of cardiovascular events (CVE) in patients with SLE. However, results of previous studies are diverse. The objectives of this study were to report number, type and those factors associated with CVE in patients with SLE in a large, single-center, ethnically diverse cohort with a long follow-up duration.
Medical records of patients treated at the Lupus Clinic at University College London Hospital (UCLH) between 1979 and 2020 were retrospectively reviewed. Data about CVE, traditional cardiovascular risk factors, demographic and disease features, and treatment history were collected. Only patients with complete available information were included in the study. Regression analyses were performed to identify factors associated with CVE.
Four hundred and nineteen patients were included in the study. Maximum follow-up length was 40 years. Seventy-one (17%) patients had at least one CVE. Multivariable analysis showed that only antiphospholipid antibody positivity (p-value<0.001) was associated with CVE. When analysing different types of CVE, antiphospholipid antibodies were specifically associated with both venous thromboembolic events (p-value<0.001) and cerebrovascular events (p-value=0.007). Dedicated subanalyses revealed that cumulative glucocorticoid dose (p-value=0.010) and a diagnosis of SLE before 2000 (p-value<0.001) were significantly associated with CVE.
Cardiovascular disease is highly prevalent among patients with SLE and is associated with antiphospholipid antibodies, glucocorticoid therapy, and diagnosis before 2000.</description><identifier>ISSN: 0049-0172</identifier><identifier>EISSN: 1532-866X</identifier><identifier>DOI: 10.1016/j.semarthrit.2023.152226</identifier><identifier>PMID: 37201214</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Antibodies, Antiphospholipid ; Antiphospholipid antibodies ; Cardiovascular disease ; Cardiovascular Diseases - complications ; Cardiovascular Diseases - etiology ; Damage ; Follow-Up Studies ; Glucocorticoid ; Glucocorticoids - therapeutic use ; Humans ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - drug therapy ; Retrospective Studies ; Risk Factors ; Systemic lupus erythematosus</subject><ispartof>Seminars in arthritis and rheumatism, 2023-08, Vol.61, p.152226-152226, Article 152226</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c424t-6c5d4b4e9d32b3408a96516c9751695142f07fc6befdd2805e8b2909e526a4883</citedby><cites>FETCH-LOGICAL-c424t-6c5d4b4e9d32b3408a96516c9751695142f07fc6befdd2805e8b2909e526a4883</cites><orcidid>0000-0001-7650-2582 ; 0000-0003-2346-4484</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.semarthrit.2023.152226$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37201214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Farina, Nicola</creatorcontrib><creatorcontrib>Webster, Jemma</creatorcontrib><creatorcontrib>Luo, Weike</creatorcontrib><creatorcontrib>Garelick, Daniela</creatorcontrib><creatorcontrib>Pinto, Sara Moreira</creatorcontrib><creatorcontrib>Isenberg, David</creatorcontrib><creatorcontrib>Rahman, Anisur</creatorcontrib><title>Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up</title><title>Seminars in arthritis and rheumatism</title><addtitle>Semin Arthritis Rheum</addtitle><description>Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular risk. Several traditional and disease-specific risk factors have been shown to correlate with the occurrence of cardiovascular events (CVE) in patients with SLE. However, results of previous studies are diverse. The objectives of this study were to report number, type and those factors associated with CVE in patients with SLE in a large, single-center, ethnically diverse cohort with a long follow-up duration.
Medical records of patients treated at the Lupus Clinic at University College London Hospital (UCLH) between 1979 and 2020 were retrospectively reviewed. Data about CVE, traditional cardiovascular risk factors, demographic and disease features, and treatment history were collected. Only patients with complete available information were included in the study. Regression analyses were performed to identify factors associated with CVE.
Four hundred and nineteen patients were included in the study. Maximum follow-up length was 40 years. Seventy-one (17%) patients had at least one CVE. Multivariable analysis showed that only antiphospholipid antibody positivity (p-value<0.001) was associated with CVE. When analysing different types of CVE, antiphospholipid antibodies were specifically associated with both venous thromboembolic events (p-value<0.001) and cerebrovascular events (p-value=0.007). Dedicated subanalyses revealed that cumulative glucocorticoid dose (p-value=0.010) and a diagnosis of SLE before 2000 (p-value<0.001) were significantly associated with CVE.
Cardiovascular disease is highly prevalent among patients with SLE and is associated with antiphospholipid antibodies, glucocorticoid therapy, and diagnosis before 2000.</description><subject>Antibodies, Antiphospholipid</subject><subject>Antiphospholipid antibodies</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - complications</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Damage</subject><subject>Follow-Up Studies</subject><subject>Glucocorticoid</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Systemic lupus erythematosus</subject><issn>0049-0172</issn><issn>1532-866X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1DAQhi0EokvLKyAfuWSxHcdJjlBRQKrEpZW4WY490XqVxMFjb7UvwHPjNgWOXGYO8838M_MTQjnbc8bVh-MeYTYxHaJPe8FEveeNEEK9IDve1KLqlPrxkuwYk33FeCsuyBvEI2OcK9a-Jhd1KxgXXO7IrxtjU4hIDWKw3iRw9MGnA7UmOh9OBm2eTKRwgiUh9QvFMyaYvaVTXjNSiOd0KMukgPmpbugclmALHgtkwyHEtI3MK02BSkbPYIpiGOkYpik8VHm9Iq9GMyG8fc6X5P7m89311-r2-5dv1x9vKyuFTJWyjZODhN7VYqgl60yvGq5s35bYN1yKkbWjVQOMzomONdANomc9NEIZ2XX1JXm_zV1j-JkBk549Wpgms0DIqEXHVavqVqqCdhtqY0CMMOo1-vL0s-ZMP7qgj_qfC_rRBb25UFrfPavkYQb3t_HP2wvwaQOg3HryEDVaD4sF5yPYpF3w_1f5DQ90oFs</recordid><startdate>202308</startdate><enddate>202308</enddate><creator>Farina, Nicola</creator><creator>Webster, Jemma</creator><creator>Luo, Weike</creator><creator>Garelick, Daniela</creator><creator>Pinto, Sara Moreira</creator><creator>Isenberg, David</creator><creator>Rahman, Anisur</creator><general>Elsevier Inc</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-7650-2582</orcidid><orcidid>https://orcid.org/0000-0003-2346-4484</orcidid></search><sort><creationdate>202308</creationdate><title>Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up</title><author>Farina, Nicola ; Webster, Jemma ; Luo, Weike ; Garelick, Daniela ; Pinto, Sara Moreira ; Isenberg, David ; Rahman, Anisur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c424t-6c5d4b4e9d32b3408a96516c9751695142f07fc6befdd2805e8b2909e526a4883</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies, Antiphospholipid</topic><topic>Antiphospholipid antibodies</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - complications</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Damage</topic><topic>Follow-Up Studies</topic><topic>Glucocorticoid</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Farina, Nicola</creatorcontrib><creatorcontrib>Webster, Jemma</creatorcontrib><creatorcontrib>Luo, Weike</creatorcontrib><creatorcontrib>Garelick, Daniela</creatorcontrib><creatorcontrib>Pinto, Sara Moreira</creatorcontrib><creatorcontrib>Isenberg, David</creatorcontrib><creatorcontrib>Rahman, Anisur</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Seminars in arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Farina, Nicola</au><au>Webster, Jemma</au><au>Luo, Weike</au><au>Garelick, Daniela</au><au>Pinto, Sara Moreira</au><au>Isenberg, David</au><au>Rahman, Anisur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up</atitle><jtitle>Seminars in arthritis and rheumatism</jtitle><addtitle>Semin Arthritis Rheum</addtitle><date>2023-08</date><risdate>2023</risdate><volume>61</volume><spage>152226</spage><epage>152226</epage><pages>152226-152226</pages><artnum>152226</artnum><issn>0049-0172</issn><eissn>1532-866X</eissn><abstract>Systemic lupus erythematosus (SLE) is associated with an increased cardiovascular risk. Several traditional and disease-specific risk factors have been shown to correlate with the occurrence of cardiovascular events (CVE) in patients with SLE. However, results of previous studies are diverse. The objectives of this study were to report number, type and those factors associated with CVE in patients with SLE in a large, single-center, ethnically diverse cohort with a long follow-up duration.
Medical records of patients treated at the Lupus Clinic at University College London Hospital (UCLH) between 1979 and 2020 were retrospectively reviewed. Data about CVE, traditional cardiovascular risk factors, demographic and disease features, and treatment history were collected. Only patients with complete available information were included in the study. Regression analyses were performed to identify factors associated with CVE.
Four hundred and nineteen patients were included in the study. Maximum follow-up length was 40 years. Seventy-one (17%) patients had at least one CVE. Multivariable analysis showed that only antiphospholipid antibody positivity (p-value<0.001) was associated with CVE. When analysing different types of CVE, antiphospholipid antibodies were specifically associated with both venous thromboembolic events (p-value<0.001) and cerebrovascular events (p-value=0.007). Dedicated subanalyses revealed that cumulative glucocorticoid dose (p-value=0.010) and a diagnosis of SLE before 2000 (p-value<0.001) were significantly associated with CVE.
Cardiovascular disease is highly prevalent among patients with SLE and is associated with antiphospholipid antibodies, glucocorticoid therapy, and diagnosis before 2000.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>37201214</pmid><doi>10.1016/j.semarthrit.2023.152226</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-7650-2582</orcidid><orcidid>https://orcid.org/0000-0003-2346-4484</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-0172 |
| ispartof | Seminars in arthritis and rheumatism, 2023-08, Vol.61, p.152226-152226, Article 152226 |
| issn | 0049-0172 1532-866X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2816763746 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Antibodies, Antiphospholipid Antiphospholipid antibodies Cardiovascular disease Cardiovascular Diseases - complications Cardiovascular Diseases - etiology Damage Follow-Up Studies Glucocorticoid Glucocorticoids - therapeutic use Humans Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - drug therapy Retrospective Studies Risk Factors Systemic lupus erythematosus |
| title | Factors associated with cardiovascular events in systemic lupus erythematosus in a monocentric cohort with up to 40 years of follow-up |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T08%3A37%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20associated%20with%20cardiovascular%20events%20in%20systemic%20lupus%20erythematosus%20in%20a%20monocentric%20cohort%20with%20up%20to%2040%20years%20of%20follow-up&rft.jtitle=Seminars%20in%20arthritis%20and%20rheumatism&rft.au=Farina,%20Nicola&rft.date=2023-08&rft.volume=61&rft.spage=152226&rft.epage=152226&rft.pages=152226-152226&rft.artnum=152226&rft.issn=0049-0172&rft.eissn=1532-866X&rft_id=info:doi/10.1016/j.semarthrit.2023.152226&rft_dat=%3Cproquest_cross%3E2816763746%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2816763746&rft_id=info:pmid/37201214&rft_els_id=S0049017223000689&rfr_iscdi=true |